SCHEMBL8010129

SCHEMBL8010129

N=C(N)NCCC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](N)CCCCN)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 9/20 0.45
NPY1R P25929 5/20 0.45
NPY2R P49146 4/20 0.45
NPY5R Q15761 4/20 0.45
NOD1 Q9Y239 3/20 0.44
GNAI3 P08754 1/20 0.43
GNAO1 P09471 1/20 0.43
GNAI1 P63096 1/20 0.43
TERT O14746 1/20 0.42
CD40 P25942 1/20 0.40
NMT2 O60551 1/20 0.40
NMT1 P30419 1/20 0.40
SLC15A2 Q16348 1/20 0.39
PRMT5 O14744 1/20 0.39
CARM1 Q86X55 1/20 0.39
PRMT1 Q99873 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
PRMT7 Q9NVM4 1/20 0.39
SLC6A5 Q9Y345 1/20 0.39
FOLH1 Q04609 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8010124 1.00 NPY4R (0.45) NPY4RNPY1RNPY2RNPY5RNOD1
SCHEMBL31406583 0.97 NOD1 (0.47) NPY4RNPY1RNPY2RNPY5RNOD1
SCHEMBL30497050 0.97 NOD1 (0.47) NPY4RNPY1RNPY2RNPY5RNOD1
SCHEMBL30395232 0.96 NPY4R (0.45) NPY4RNPY1RNPY2RNPY5RNOD1
SCHEMBL31047157 0.95 FOLH1 (0.48) NPY4RNPY1RNPY2RNPY5RNOD1
SCHEMBL30063019 0.94 NPY4R (0.42) NPY4RNPY1RNPY2RNPY5RNOD1
SCHEMBL29378785 0.93 FNTA (0.46) NPY4RNPY1RNPY2RNPY5RNMT2
SCHEMBL31691755 0.93 NPY4R (0.44) NPY4RNPY1RNPY2RNPY5RGNAI3
SCHEMBL30880861 0.92 FOLH1 (0.47) NPY4RNPY1RNPY2RNPY5RNOD1
SCHEMBL31343396 0.92 NPY4R (0.45) NPY4RNPY1RNPY2RNPY5RNOD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11299509-B2 Trigger-activatable sugar conjugates for cancer-selective labeling and targeting THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2022-04-12 US disclosed
WO-2000034473-A2 SEVEN TRANSMEMBRANE DOMAIN RECEPTOR ZSIG56 ZYMOGENETICS, INC. (US) 2000-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11299509-B2 Trigger-activatable sugar conjugates for cancer-selective labeling and targeting FUT6, GPI, CSGALNACT1 NPY4R 2404/4885NPY1R 2500/4885NPY2R 3646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.